These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 2067409)

  • 21. No regression of renal amyloid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy.
    Simsek I; Kaya A; Erdem H; Pay S; Yenicesu M; Dinc A
    J Nephrol; 2010; 23(1):119-23. PubMed ID: 20091495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients.
    Guillevin L; Durand-Gasselin B; Cevallos R; Gayraud M; Lhote F; Callard P; Amouroux J; Casassus P; Jarrousse B
    Arthritis Rheum; 1999 Mar; 42(3):421-30. PubMed ID: 10088763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal involvement in AA amyloidosis: clinical outcomes and survival.
    Yilmaz M; Unsal A; Sokmen M; Kaptanogullari OH; Alkim C; Kabukcuoglu F; Ozagari A; Bor E
    Kidney Blood Press Res; 2013; 37(1):33-42. PubMed ID: 23548761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor.
    Vela-Ojeda J; García-Ruiz Esparza MA; Padilla-González Y; Sánchez-Cortes E; García-Chávez J; Montiel-Cervantes L; Reyes-Maldonado E; Majluf-Cruz A; Mayani H
    Ann Hematol; 2009 Jan; 88(1):59-66. PubMed ID: 18648809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Systemic AA amyloidosis induced by benign neoplasms].
    Bestard Matamoros O; Poveda Monje R; Ibernon Vilaró M; Carrera Plans M; Grinyó Boira JM
    Nefrologia; 2008; 28(1):93-8. PubMed ID: 18336138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of amyloidosis on long-term survival in kidney transplantation.
    Emiroglu R; Başaran O; Pehlivan S; Ozdemir FN; Colak T; Moray G; Noyan T; Haberal M
    Transplant Proc; 2005 Sep; 37(7):2967-8. PubMed ID: 16213276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The premortem recognition of systemic senile amyloidosis with cardiac involvement.
    Kyle RA; Spittell PC; Gertz MA; Li CY; Edwards WD; Olson LJ; Thibodeau SN
    Am J Med; 1996 Oct; 101(4):395-400. PubMed ID: 8873510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing heart transplantation: results of a multicenter survey.
    Hosenpud JD; Uretsky BF; Griffith BP; O'Connell JB; Olivari MT; Valantine HA
    J Heart Transplant; 1990; 9(4):346-50. PubMed ID: 2398427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ten years' experience of an amyloid clinic--a clinicopathological survey.
    Browning MJ; Banks RA; Tribe CR; Hollingworth P; Kingswood C; Mackenzie JC; Bacon PA
    Q J Med; 1985 Mar; 54(215):213-27. PubMed ID: 3991877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement.
    Pellikka PA; Holmes DR; Edwards WD; Nishimura RA; Tajik AJ; Kyle RA
    Arch Intern Med; 1988 Mar; 148(3):662-6. PubMed ID: 3341867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
    Bird JM; Fuge R; Sirohi B; Apperley JF; Hunter A; Snowden J; Mahendra P; Milligan D; Byrne J; Littlewood T; Fegan C; McQuaker G; Pagliuca A; Johnson P; Rahemtulla A; Morris C; Marks DI;
    Br J Haematol; 2006 Aug; 134(4):385-90. PubMed ID: 16822294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Gastrointestinal amyloidosis].
    Lévy A; Lender M
    Nouv Presse Med; 1976 Sep; 5(31):1969-73. PubMed ID: 185589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical characteristics and genetic background of secondary amyloidosis associated with rheumatoid arthritis in Japanese].
    Nakai H; Ozaki S; Kano S; Goto M; Komatsubara Y; Kondo S; Shimizu M; Takasugi K; Hanyu T; Matsuno H; Matsubara T; Yamana S
    Ryumachi; 1996 Feb; 36(1):25-33. PubMed ID: 8711535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and biochemical outcome of renal amyloidosis.
    Odabas AR; Cetinkaya R; Selcuk Y; Erman Z; Bilen H
    Int J Clin Pract; 2002 Jun; 56(5):342-4. PubMed ID: 12137441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Is the current treatment of primary and secondary amyloidosis effective?].
    Rysavá R; Spicka I; Merta M; Tesar V; Trnĕný M
    Cas Lek Cesk; 2003; 142(6):370-2. PubMed ID: 12924037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
    Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
    Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Renal involvement in amyloidosis. Clinical outcomes, evolution and survival].
    Esteve V; Almirall J; Ponz E; García N; Ribera L; Larrosa M; Andreu X; García M
    Nefrologia; 2006; 26(2):212-7. PubMed ID: 16808259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes and survival in AA amyloidosis patients.
    Ayar Y; Ersoy A; Oksuz MF; Ocakoglu G; Vuruskan BA; Yildiz A; Isiktas E; Oruc A; Celikci S; Arslan I; Sahin AB; Güllülü M
    Rev Bras Reumatol Engl Ed; 2017; 57(6):535-544. PubMed ID: 29173691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases.
    Fernández-Nebro A; Olivé A; Castro MC; Varela AH; Riera E; Irigoyen MV; García de Yébenes MJ; García-Vicuña R
    Am J Med; 2010 May; 123(5):454-61. PubMed ID: 20399323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia.
    Gertz MA; Kyle RA; Noel P
    J Clin Oncol; 1993 May; 11(5):914-20. PubMed ID: 8487054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.